The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease ...

Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Finding offers potential new target for treatmentPsoriasis, a painful and uncomfortable inflammatory skin condition that ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...